Jean Jacques Bienaime

September 28, 2026

Keros Therapeutics Doses First Patient in Phase 2 Rinvatercept Trial. Keros Therapeutics has announced the dosing of the first patient in a Phase 2 clinical trial evaluating rinvatercept for Duchenne Muscular Dystrophy. This milestone marks a significant step in the development of the company's lead candidate. The stock is currently trading near its support level, with analysts setting an average price target of $19.83.

October 4, 2026

Ascendis Pharma signs BioMarin license deal, ends litigation. Ascendis Pharma has reached a licensing agreement with BioMarin for its TransCon Cnp, Navepegritide, and Yuviwel products. Under the deal, Ascendis will pay royalties on sales in the U.S. and Europe until May 2030, and all pending legal disputes between the two companies have been dismissed. This resolution removes a significant legal uncertainty for the stock, which is currently trading near its 52-week low.

October 17, 2026

Incyte receives mixed analyst updates with price target changes. Incyte saw two recent analyst actions with differing views. Truist Securities raised its price target to $115 while maintaining a Hold rating. Conversely, HC Wainwright reiterated a Buy rating and kept its target at $152. These moves reflect a wide range of expectations among analysts for the stock's future performance.

October 12, 2026

Immunome files Nasdaq inducement grant report, sees higher volume. Immunome disclosed inducement grants in a filing required by Nasdaq Listing Rule 5635(c)(4). The disclosure shows the company is meeting reporting obligations for equity compensation. At the same time, the stock appeared among Benzinga’s recent volume movers, indicating a noticeable increase in trading activity. These items together suggest regulatory compliance and heightened market attention.

October 4, 2026

BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership. BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.